Altre lingue Natera, Inc.

Azioni

NTRA

US6323071042

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
91,28 ^USD	-0,24%		+4,58%	+45,72%

18/04	L'insider di Natera ha venduto azioni per un valore di 7.265.651 dollari, secondo un recente deposito SEC	MT
18/04	Un insider di Natera ha venduto azioni per un valore di 634.797 dollari, secondo un recente documento della SEC	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications	22/04
Natera Insider Sold Shares Worth $7,265,651, According to a Recent SEC Filing	18/04
Natera Insider Sold Shares Worth $634,797, According to a Recent SEC Filing	18/04
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera, Inc. Announces Publication of Larger Prospective dd-cfDNA Study in Kidney Transplantation	11/04
Natera Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heart dd-cfDNA Test for Heart Transplant Recipients	09/04
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients	08/04
Natera, Inc. Announces New Data from Two Studies Extending the Clinical Validation of Its Prospera Heartd-cfDNA Test for Heart Transplant Recipients	08/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	08/04
North American Morning Briefing : Inflation Data, -2-	08/04
Natera Reports Positive Surveillance Analysis From Phase 3 Study of Bladder Cancer Test; Shares Rise	05/04
Natera Insider Sold Shares Worth $2,468,822, According to a Recent SEC Filing	05/04
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer	05/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103, A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	02/04
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer	01/04
Natera, Inc. and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 A Randomized, Phase Ii/Iii Adjuvant Trial in Urothelial Cancer	01/04
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer	18/03
Natera, Inc. Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera?? in Stage II Colorectal Cancer	18/03
Natera, Inc. - New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	15/03
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease	14/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Natera, Inc.

Azioni

NTRA

US6323071042

Altre lingue

Filtri